PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
03-Nov-2025 Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma ACCESS Newswire
03-Nov-2025 Ascelia Pharma Announces Management Changes to Support Future Growth ACCESS Newswire
03-Nov-2025 Obesity Drugs Market 2021 Size, Revenue Analysis, Sales, Share and Research Depth Study 2027 Medi-Tech Insights
03-Nov-2025 From Genomics to Proteomics: Esoteric Testing Market Leads the Next Diagnostic Revolution Market Reports
03-Nov-2025 AI in Ultrasound Imaging Market Depth Study, Analysis, Key Drivers, Top Players, Trends and Forecast 2030 Medi-Tech Insights
03-Nov-2025 Innovation at the Cellular Frontier: The mRNA Cancer Vaccines and Therapeutics Market Unfolds 2025-2035 Market Reports
03-Nov-2025 Vicore Announces The Nomination Committee For The 2026 Annual General Meeting ACCESS Newswire
03-Nov-2025 Faron Hits Key Milestone With Bexmab Phase 2 Completion, Advances To Registrational Trial With Fda Alignment ACCESS Newswire
03-Nov-2025 iZafe Group's quarterly report Q3, July-September 2025 ACCESS Newswire
01-Nov-2025 Kenner Family Research Fund and Entertainment to Affect Change (E2AC) Launch "30 Stories, 30 Days" Campaign for World Pancreatic Cancer Awareness Month ACCESS Newswire
31-Oct-2025 New Study Highlights Better Healing Outcomes for Pressure Ulcers With Advanced Wound Care Products  ACCESS Newswire
31-Oct-2025 Automotive Active Health Monitoring System Market Poised for Explosive Growth, Projected to Reach USD 31.38 Billion by 2032 Ameco Research
31-Oct-2025 Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight ACCESS Newswire
31-Oct-2025 Global Cancer Therapeutics Market to Reach USD 437.3 Billion by 2032, Growing at 10.8% CAGR — Ameco Research Ameco Research
31-Oct-2025 Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration Vesper Bio
31-Oct-2025 Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic Urticaria Alys Pharmaceuticals
31-Oct-2025 Moberg Pharma’s Nomination Committee appointed Moberg Pharma
31-Oct-2025 Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development Galapagos
31-Oct-2025 HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus HighTide Therapeutics Inc
31-Oct-2025 Scot’s share of UK’s £27.4bn spend on alcohol likely to be significant. It’s time to cut back. Sinclair method UK